Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Nov 3, 2020
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Acutelines trial is a research study aimed at improving how we recognize and treat serious medical conditions that require urgent care, like sepsis, pneumonia, and kidney injury. By collecting health data and samples from patients in emergency situations, the researchers hope to better understand these acute diseases and predict how patients will recover. This information will help doctors provide more personalized treatment in the future.
To participate in the trial, patients must be experiencing serious health issues and be categorized as needing immediate care according to a specific triage system. This includes those showing signs of shock or suspected sepsis, among other conditions. If eligible, participants can expect to have their health information and samples collected during their emergency treatment. It’s important to note that this study is currently recruiting participants, and it aims to make a significant impact on emergency medicine practices.
Gender
ALL
Eligibility criteria
- Inclusion Criteria, at least one of the following:
- • Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system;
- • Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS;
- • Shock
- • Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria)
- • Acute kidney injury (AKI)
- • Anaphylactic reaction
- • Syncope
- • Intoxication
- • Thrombosis
- • Pulmonary embolism
- • Bleeding while using anti-coagulant drugs
- • Gastro-intestinal bleeding
- • Electrolyte disturbance
- Exclusion Criteria:
- • Referred for organ transplantation as recipient
- • Transfer from other hospital
- • Accidental contact patient material (i.e. internal work-related accident)
- • While data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories \[red or orange\] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, , Netherlands
Patients applied
Trial Officials
Ewoud ter Avest, MD, PhD
Study Chair
University Medical Center Groningen
Jan ter Maaten, MD, PhD
Study Director
University Medical Center Groningen
Hjalmar Bouma, MD, PhD
Study Director
University Medical Center Groningen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials